Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:4948 |
Name | gallbladder carcinoma |
Definition | A gallbladder cancer that has_material_basis_in abnormally proliferating cells derives_from epithelial cells. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer gastrointestinal system cancer hepatobiliary system cancer biliary tract cancer gallbladder cancer gallbladder carcinoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
ATM S1905Ifs*25 | Olaparib | gallbladder carcinoma | predicted - sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01174121 | Phase II | Pembrolizumab Cyclophosphamide + Fludarabine Aldesleukin | Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer | Recruiting | USA | 0 |
NCT02042443 | Phase II | Fluorouracil + Leucovorin Capecitabine Trametinib | Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery | Completed | USA | 0 |
NCT02115542 | Phase II | Regorafenib | Single Agent Regorafenib in Refractory Advanced Biliary Cancers | Completed | USA | 0 |
NCT02151084 | Phase II | Cisplatin + Gemcitabine + Selumetinib | A Study of Different Dosing Schedules of Selumetinib With Cisplatin/Gemcitabine (CIS/GEM) Versus CIS/GEM Alone in Biliary Cancer | Active, not recruiting | CAN | 0 |
NCT02631590 | Phase II | Cisplatin + Copanlisib + Gemcitabine | Copanlisib (BAY 80-6946) in Combination With Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma | Completed | USA | 0 |
NCT02829918 | Phase II | Nivolumab | Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers | Completed | USA | 0 |
NCT03260712 | Phase II | Cisplatin + Gemcitabine + Pembrolizumab | Pembrolizumab in Biliary Tract Cancer | Completed | GBR | ESP | DEU | 0 |
NCT03704480 | Phase II | Durvalumab + Tremelimumab | Durvalumab Plus Tremelimumab Combination Immunotherapy With or Without Weekly Paclitaxel in Patients With Advanced Biliary Tract Carcinoma (BTC) After Failure of Platinum-based Chemotherapy (IMMUNO-BIL) | Active, not recruiting | FRA | 0 |
NCT04003896 | Phase II | Abemaciclib | A Study to Evaluate Abemaciclib in Advanced Biliary Tract Carcinoma Who Failed Prior First Line Therapy | Terminated | USA | 0 |
NCT04068194 | Phase Ib/II | Avelumab Avelumab + Peposertib | Testing the Combination of New Anti-cancer Drug Nedisertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies | Recruiting | USA | 0 |
NCT04137289 | Phase I | BI 905711 | A First-in-human Phase Ia/b, Open Label, Multicentre, Dose Escalation Study of BI 905711 in Patients With Advanced Gastrointestinal Cancers | Completed | USA | FRA | ESP | DEU | BEL | 3 |
NCT04203160 | Phase Ib/II | Cisplatin + Gemcitabine Cisplatin + CPI-613 + Gemcitabine | Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04) | Completed | USA | 0 |
NCT04430738 | Phase Ib/II | Pembrolizumab + Trastuzumab + Tucatinib Fluorouracil + Leucovorin + Oxaliplatin + Trastuzumab + Tucatinib Capecitabine + Oxaliplatin + Pembrolizumab + Trastuzumab + Tucatinib Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab + Trastuzumab + Tucatinib Capecitabine + Oxaliplatin + Trastuzumab + Tucatinib | Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers | Active, not recruiting | USA | 1 |
NCT04677504 | Phase II | Atezolizumab + Cisplatin + Gemcitabine Atezolizumab + Bevacizumab + Cisplatin + Gemcitabine | A Study of Atezolizumab With or Without Bevacizumab in Combination With Cisplatin Plus Gemcitabine in Patients With Untreated, Advanced Biliary Tract Cancer | Completed | USA | TUR | POL | ITA | GBR | ESP | 7 |
NCT04941287 | Phase II | Atezolizumab + Varlilumab Atezolizumab + Cobimetinib + Varlilumab | Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of A Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer | Active, not recruiting | USA | 0 |
NCT04969887 | Phase II | Ipilimumab + Nivolumab | Combination Immunotherapy in Rare Cancers Under InvesTigation (MOST-CIRCUIT) | Active, not recruiting | NZL | AUS | 0 |
NCT05194072 | Phase I | SGN-B7H4V | A Study of SGN-B7H4V in Advanced Solid Tumors | Recruiting | USA | ITA | GBR | ESP | DEU | CAN | 0 |
NCT05239169 | Phase II | Capecitabine + Durvalumab + Tremelimumab Durvalumab + Tremelimumab | Immunotherapy With Durva and Treme With or Without Capecitabine in Adjuvant Treatment for Biliary Tract Cancer | Active, not recruiting | DEU | 0 |
NCT05615818 | Phase III | Niraparib ZW25 Binimetinib + Encorafenib Futibatinib Cisplatin + Gemcitabine Neratinib + Trastuzumab Ivosidenib | Personalized Medicine for Advanced Biliary Cancer Patients (SAFIR-ABC10) | Recruiting | GBR | FRA | BEL | 0 |
NCT05712356 | Phase II | CEND-1 + Cisplatin + Durvalumab + Gemcitabine Cisplatin + Durvalumab + Gemcitabine Paclitaxel Docetaxel CEND-1 + Docetaxel CEND-1 + Paclitaxel | A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors (BOLSTER) | Recruiting | USA | ESP | 0 |
NCT06529718 | Phase II | Fluorouracil + Leucovorin + Oxaliplatin Ivonescimab | Testing Ivonescimab Versus FOLFOX in Advanced Biliary Tract Cancer Patients (SEVILLA) | Not yet recruiting | GBR | FRA | BEL | 0 |
NCT06546969 | Phase I | Cisplatin + Durvalumab + Gemcitabine | Chemoimmunotherapy Combined With Hyperthermia and Spatially-Fractionated Radiotherapy in Advanced Biliary Tract Cancer | Recruiting | USA | 0 |